Evidence map›Paper›PMID 41000008›Full record

SynthesisHypertension (Dallas, Tex. : 1979)2025

Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Zoe Argeros, Xiaoye Xu, Buna Bhandari, Katie Harris, Rhian M Touyz, Aletta E Schutte

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Hypertension (Dallas, Tex. : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Role of an Angiotensin II Type-1 Receptor (ATBiological trace element research · 2026
    Article
  3. Magnesium and blood pressure regulation: systemic and renal mechanisms.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  4. Magnesium: Hype and Health Benefits.Current nutrition reports · 2026
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zoe ArgerosSchool of Population Health, University of New South Wales, Sydney, Australia (Z.A., X.X., A.E.S.).
Xiaoye XuSchool of Population Health, University of New South Wales, Sydney, Australia (Z.A., X.X., A.E.S.).ORCID 0000-0003-4787-6547
Buna BhandariDepartment of Global Health and Population, Harvard T H Chan School of Public Health, Boston (B.B.).ORCID 0000-0002-0102-8844
Katie HarrisThe George Institute for Global Health, Sydney, Australia (X.X., K.H., A.E.S.).ORCID 0000-0003-2444-2869
Rhian M TouyzDepartment of medicine and Department of family medicine, Research Institute of McGill University Health Centre, McGill University, Montreal, Canada (R.M.T.).ORCID 0000-0003-0670-0887
Aletta E SchutteSchool of Population Health, University of New South Wales, Sydney, Australia (Z.A., X.X., A.E.S.).ORCID 0000-0001-9217-4937

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are inconsistent reports regarding the effect of magnesium intake on blood pressure (BP) across hypertensive and normotensive populations.

methodsWe performed a meta-analysis and dose-response analysis to explore the relationship between magnesium supplementation and BP in randomized-controlled trials with a duration of ≥4 weeks, using a cubic spline regression model.

resultsThirty-eight randomized controlled trials involving 2709 participants were eligible for inclusion. Studies included an elemental magnesium dose from 82.3 mg to 637 mg with a median dose of 365 mg and a median intervention period of 12 weeks. Mean differences of changes in BP were calculated by random effects meta-analysis. Magnesium intake resulted in a reduction in systolic BP of -2.81 mm Hg (95% CI, -4.32 to -1.29) and diastolic BP by -2.05 mm Hg (95% CI, -3.23 to -0.88) compared with placebo. Hypertensive individuals on BP-lowering medication and individuals with hypomagnesemia yielded greater systolic BP reductions of -7.68 and -5.97 mm Hg, respectively (

conclusionsOur findings support the beneficial effect of magnesium on reducing BP among populations with hypertension and hypomagnesemia, although effects should be interpreted with caution due to high heterogeneity of studies. Larger, well-designed studies assessing higher magnesium doses are needed to refine the dose-response relationship between magnesium intake and BP and identify potential optimal supplementation strategies for subpopulations.

Indexed as

Blood PressureDietary SupplementsHypertensionMagnesiumDose-Response Relationship, DrugHumansRandomized Controlled Trials as TopicMagnesiumblood pressurecardiovascular diseasediethypertensionmagnesium

Identifiers

PMID41000008
PMCPMC12529988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.